Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
MediumReport
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
MediumReport
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $6.00. They now have a "buy" rating on the stock.
MediumReport
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $6.00. They now have a "buy" rating on the stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Morgan Stanley from $15.00 to $5.00. They now have an "overweight" rating on the stock.
MediumReport
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Morgan Stanley from $15.00 to $5.00. They now have an "overweight" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: